Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 5/2013

01.09.2013

Cardiac metabolism in hypertrophy and heart failure: implications for therapy

verfasst von: N. Siddiqi, S. Singh, R. Beadle, D. Dawson, M. Frenneaux

Erschienen in: Heart Failure Reviews | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The heart consumes huge amounts of energy to fulfil its function as a relentless pump. A highly sophisticated system of energy generation based on flexibility of substrate use and efficient energy production, effective energy sensing and energy transfer ensures function of the healthy heart across a range of physiological situations. In left ventricular hypertrophy and heart failure, these processes become disturbed, leading as will be discussed to impaired cardiac energetic status and to further impairment of cardiac function. These metabolic disturbances form a potential target for therapy.
Literatur
1.
Haldeman GA, Croft JB, Giles WH, Rashidee A (1999) Hospitalization of patients with heart failure: National hospital discharge survey 1985–1995. Am Heart J 137(2):352–360PubMedCrossRef
2.
McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83(5):596–602PubMedCrossRef
3.
Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8(1):30–41PubMedCrossRef
4.
Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF et al (1999) Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation 100(20):2113–2118PubMedCrossRef
5.
Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W et al (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7):2190–2196PubMedCrossRef
6.
Weiss RG, Gerstenblith G, Bottomley PA (2005) ATP flux through creatine kinase in the normal, stressed, and failing human heart. P Natl Acad Sci USA 102(3):808–813CrossRef
7.
Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG (2006) Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114(11):1151–1158PubMedCrossRef
8.
Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L et al (2009) Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 54(5):402–409PubMedCrossRef
9.
Beyerbacht HP, Lamb HJ, van Der Laarse A, Vliegen HW, Leujes F, Hazekamp MG et al (2001) Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219(3):637–643PubMed
10.
Machann W, Breunig F, Weidemann F, Sandstede J, Hahn D, Kostler H et al (2011) Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Eur J Heart Fail 13(3):278–283PubMedCrossRef
11.
Bunse M, Bit-Avragim N, Riefflin A, Perrot A, Schmidt O, Kreuz FR et al (2003) Cardiac energetics correlates to myocardial hypertrophy in Friedreich’s ataxia. Ann Neurol 53(1):121–123PubMedCrossRef
12.
Ashrafian H, Redwood C, Blair E, Watkins H (2003) Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 19(5):263–268PubMedCrossRef
13.
Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz T, Pravenec M et al (2001) Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276(26):23661–23666PubMedCrossRef
14.
Labarthe F, Khairallah M, Bouchard B, Stanley WC, Des Rosiers C (2005) Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. Am J Physiol Heart Circ Physiol 288(3):H1425–H1436PubMedCrossRef
15.
Houben AJ, Beljaars JH, Hofstra L, Kroon AA, De Leeuw PW (2003) Microvascular abnormalities in chronic heart failure: a cross-sectional analysis. Microcirculation 10(6):471–478PubMed
16.
Goodwin GW, Taylor CS, Taegtmeyer H (1998) Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 273(45):29530–29539PubMedCrossRef
17.
Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M (2004) Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 1015:202–213PubMedCrossRef
18.
Camici P, Ferrannini E, Opie LH (1989) Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 32(3):217–238PubMedCrossRef
19.
Korvald C, Elvenes OP, Myrmel T (2000) Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 278(4):H1345–H1351PubMed
20.
Schrauwen P, Hesselink MKC (2004) The role of uncoupling protein 3 in fatty acid metabolism: protection against lipotoxicity? P Nutr Soc 63(2):287–292CrossRef
21.
Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K (2004) Uncoupling proteins in human heart. Lancet 364(9447):1786–1788PubMedCrossRef
22.
Murphy MP, Echtay KS, Blaikie FH, Asin-Cayuela J, Cocheme HM, Green K et al (2003) Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. J Biol Chem 278(49):48534–48545PubMedCrossRef
23.
Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116(4):434–448PubMedCrossRef
24.
Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98(5):596–605PubMedCrossRef
25.
Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T et al (1999) Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104(12):1703–1714PubMedCrossRef
26.
Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94(11):2837–2842PubMedCrossRef
27.
Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR et al (2002) Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106(5):606–612PubMedCrossRef
28.
Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G et al (2007) The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol 49(6):408–415PubMedCrossRef
29.
Finck BN (2007) The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73(2):269–277PubMedCrossRef
30.
Liao R, Jain M, Cui L, D’Agostino J, Aiello F, Luptak I et al (2002) Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106(16):2125–2131PubMedCrossRef
31.
Sorokina N, O’Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF et al (2007) Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115(15):2033–2041PubMedCrossRef
32.
Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH (1998) Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83(10):969–979PubMedCrossRef
33.
Funada J, Betts TR, Hodson L, Humphreys SM, Timperley J, Frayn KN et al (2009) Substrate utilization by the failing human heart by direct quantification using arterio-venous blood sampling. PLoS ONE 4(10):e7533PubMedCrossRef
34.
Paolisso G, Gambardella A, Galzerano D, D’Amore A, Rubino P, Verza M et al (1994) Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 43(2):174–179PubMedCrossRef
35.
Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ et al (2001) An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J Nucl Med 42(1):55–62PubMed
36.
Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40(2):271–277PubMedCrossRef
37.
Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K et al (1994) Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23(7):1617–1624PubMedCrossRef
38.
Taegtmeyer H (1983) On the inability of ketone bodies to serve as the only energy providing substrate for rat heart at physiological work load. Basic Res Cardiol 78(4):435–450PubMedCrossRef
39.
Tardif A, Julien N, Pelletier A, Thibault G, Srivastava AK, Chiasson JL et al (2001) Chronic exposure to beta-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. Am J Physiol Endocrinol Metab 281(6):E1205–E1212PubMed
40.
Faerber G, Barreto-Perreia F, Schoepe M, Gilsbach R, Schrepper A, Schwarzer M et al. (2011) Induction of heart failure by minimally invasive aortic constriction in mice: reduced peroxisome proliferator-activated receptor gamma coactivator levels and mitochondrial dysfunction. J Thorac Cardiovasc Surg 141(2):492–500, 500.e1
41.
Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1(6):361–370PubMedCrossRef
42.
Sihag S, Cresci S, Li AY, Sucharov CC, Lehman JJ (2009) PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46(2):201–212PubMedCrossRef
43.
Maack C, Bohm M (2011) Targeting mitochondrial oxidative stress in heart failure throttling the afterburner. J Am Coll Cardiol 58(1):83–86PubMedCrossRef
44.
Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N et al (1999) Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85(4):357–363PubMedCrossRef
45.
Liu T, O’Rourke B (2008) Enhancing mitochondrial Ca2 + uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res 103(3):279–288PubMedCrossRef
46.
Marcil M, Ascah A, Matas J, Belanger S, Deschepper CF, Burelle Y (2006) Compensated volume overload increases the vulnerability of heart mitochondria without affecting their functions in the absence of stress. J Mol Cell Cardiol 41(6):998–1009PubMedCrossRef
47.
Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN (2007) Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 42(1):150–158PubMedCrossRef
48.
Sharov VG, Todor AV, Imai M, Sabbah HN (2005) Inhibition of mitochondrial permeability transition pores by cyclosporine A improves cytochrome C oxidase function and increases rate of ATP synthesis in failing cardiomyocytes. Heart Fail Rev 10(4):305–310PubMedCrossRef
49.
Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L et al (2005) Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 65(1):230–238PubMedCrossRef
50.
Tsutsui H, Ide T, Kinugawa S (2006) Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 8(9–10):1737–1744PubMedCrossRef
51.
Dai DF, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF et al (2011) Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 58(1):73–82PubMedCrossRef
52.
Ingwall JS, Atkinson DE, Clarke K, Fetters JK (1990) Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium. Eur Heart J 11 Suppl B: 108–115
53.
Lygate CA, Fischer A, Sebag-Montefiore L, Wallis J, ten Hove M, Neubauer S (2007) The creatine kinase energy transport system in the failing mouse heart. J Mol Cell Cardiol 42(6):1129–1136PubMedCrossRef
54.
Ingwall JS (2009) Energy metabolism in heart failure and remodelling. Cardiovasc Res 81(3):412–419PubMedCrossRef
55.
Mekhfi H, Veksler V, Mateo P, Maupoil V, Rochette L, Ventura-Clapier R (1996) Creatine kinase is the main target of reactive oxygen species in cardiac myofibrils. Circ Res 78(6):1016–1027PubMedCrossRef
56.
Park SJ, Zhang J, Ye Y, Ormaza S, Liang P, Bank AJ et al (2002) Myocardial creatine kinase expression after left ventricular assist device support. J Am Coll Cardiol 39(11):1773–1779PubMedCrossRef
57.
Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG (2012) Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol 59(9):802–808PubMedCrossRef
58.
Neubauer S, Remkes H, Spindler M, Horn M, Wiesmann F, Prestle J et al (1999) Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100(18):1847–1850PubMedCrossRef
59.
Wallis J, Lygate CA, Fischer A, ten Hove M, Schneider JE, Sebag-Montefiore L et al (2005) Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice. Circulation 112(20):3131–3139PubMedCrossRef
60.
Kaasik A, Veksler V, Boehm E, Novotova M, Minajeva A, Ventura-Clapier R (2001) Energetic crosstalk between organelles: architectural integration of energy production and utilization. Circ Res 89(2):153–159PubMedCrossRef
61.
Aksentijevic D, Lygate CA, Makinen K, Zervou S, Sebag-Montefiore L, Medway D et al (2010) High-energy phosphotransfer in the failing mouse heart: role of adenylate kinase and glycolytic enzymes. Eur J Heart Fail 12(12):1282–1289PubMedCrossRef
62.
Gupta A, Akki A, Wang Y, Leppo MK, Chacko VP, Foster DB et al (2012) Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest 122(1):291–302PubMedCrossRef
63.
Dzeja PP, Redfield MM, Burnett JC, Terzic A (2000) Failing energetics in failing hearts. Curr Cardiol Rep 2(3):212–217PubMedCrossRef
64.
Gt Cooper (2006) Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. Am J Physiol Heart Circ Physiol 291(3):H1003–H1014CrossRef
65.
Ventura-Clapier R, Garnier A, Veksler V (2004) Energy metabolism in heart failure. J Physiol 555(Pt 1):1–13PubMedCrossRef
66.
Nelson GS, Berger RD, Fetics BJ, Talbot M, Spinelli JC, Hare JM et al (2000) Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102(25):3053–3059PubMedCrossRef
67.
Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE et al (2006) Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114(20):2130–2137PubMedCrossRef
68.
Halbirk M, Norrelund H, Moller N, Schmitz O, Gotzsche L, Nielsen R et al (2010) Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 299(4):H1220–H1225PubMedCrossRef
69.
Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC et al (2005) Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 289(6):H2304–H2309PubMedCrossRef
70.
Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S et al (2005) Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 66(3):454–461PubMedCrossRef
71.
Turcani M, Rupp H (1997) Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96(10):3681–3686PubMedCrossRef
72.
Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW et al (2009) The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. Basic Res Cardiol 104(5):547–557PubMedCrossRef
73.
Schmidt-Schweda S, Holubarsch C (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99(1):27–35CrossRef
74.
Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P et al (2007) A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 113(4):205–212CrossRef
75.
Kennedy JA, Unger SA, Horowitz JD (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52(2):273–280PubMedCrossRef
76.
Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ (1986) Perhexiline maleate treatment for severe angina pectoris–correlations with pharmacokinetics. Int J Cardiol 13(2):219–229PubMedCrossRef
77.
Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al (2005) Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112(21):3280–3288PubMedCrossRef
78.
Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P et al (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41(10):1776–1782PubMedCrossRef
79.
Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122(16):1562–1569PubMedCrossRef
80.
Kennedy JA, Beck-Oldach K, McFadden-Lewis K, Murphy GA, Wong YW, Zhang Y et al (2006) Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol 531(1–3):13–19PubMedCrossRef
81.
Ngo D DN, Pagano D, Frenneaux M, Horowitz J (2011) How does perhexiline modulate myocardial energetics and ameliorate redox stress? Circulation 124: A14461
82.
Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 4(9):e7124PubMedCrossRef
83.
Panchal AR, Stanley WC, Kerner J, Sabbah HN (1998) Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 4(2):121–126PubMedCrossRef
84.
Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ et al (2001) Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103(20):2441–2446PubMedCrossRef
85.
Fantini E, Demaison L, Sentex E, Grynberg A, Athias P (1994) Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26(8):949–958PubMedCrossRef
86.
Kantor PF, Lucien A, Kozak R, Lopaschuk GD (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86(5):580–588PubMedCrossRef
87.
Gao D, Ning N, Niu X, Hao G, Meng Z (2011) Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 97(4):278–286PubMedCrossRef
88.
Zhang L, Lu Y, Jiang H, Sun A, Zou Y, Ge J (2012) Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 59(10):913–922PubMedCrossRef
89.
Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G et al (2006) Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27(8):942–948PubMedCrossRef
90.
Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B et al (2008) Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118(12):1250–1258PubMedCrossRef
91.
Di Napoli P, Taccardi AA, Barsotti A (2005) Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91(2):161–165PubMedCrossRef
92.
Clarke B, Wyatt KM, McCormack JG (1996) Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28(2):341–350PubMedCrossRef
93.
Maier LWR, Edelmann F, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Hasenfuss G, Jacobshagen C (2008) Ranolazine for the ttreatment of diastolic heart failure in patients with preserved ejection fraction: results from the Rali-Heart study. J Am Coll Cardiol 59(13):E865CrossRef
94.
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559PubMedCrossRef
95.
Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370(9593):1129–1136PubMedCrossRef
96.
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O et al (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51(7):2074–2081PubMedCrossRef
97.
Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD et al (2010) Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106(7):1006–1010PubMedCrossRef
98.
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12(9):694–699PubMedCrossRef
99.
Halbirk M, Norrelund H, Moller N, Holst JJ, Schmitz O, Nielsen R et al (2010) Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298(3):H1096–H1102PubMedCrossRef
100.
Nathanson D, Ullman B, Lofstrom U, Hedman A, Frick M, Sjoholm A et al (2012) Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55(4):926–935PubMedCrossRef
Metadaten
Titel
Cardiac metabolism in hypertrophy and heart failure: implications for therapy
verfasst von
N. Siddiqi
S. Singh
R. Beadle
D. Dawson
M. Frenneaux
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 5/2013
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-012-9359-2

Weitere Artikel der Ausgabe 5/2013

Heart Failure Reviews 5/2013 Zur Ausgabe

OriginalPaper

Metabolic and structural impairment of skeletal muscle in heart failure

OriginalPaper

1H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism

OriginalPaper

Mitochondrial dysfunction in heart failure

OriginalPaper

Tragic heart, magic art

OriginalPaper

Autophagy: an affair of the heart

EditorialNotes

Introduction to special issue on cardiac metabolism in hypertrophy and failure

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise